INmune Bio completes Phase I dose cohort for INKmune in mCRPC, opens Phase II

Inmune Bio, Inc.

Third and highest dose cohort of Phase I completed; no safety issues found.
Scientific Review Committee unanimously voted to open all Phase II cohorts of CaRePC trial.
Low dose cohort showed immunologic effects; higher dose cohorts to assess therapeutic benefits.
CEO R.J. Tesi noted INKmune given in outpatient setting with exemplary safety profile.
CSO Mark Lowdell invited to speak at 10th Annual Innate Killer Summit on March 4.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.